Table.
Baseline characteristics of patients
| Variable | Training cohort | P | Testing cohort | P | ||
|---|---|---|---|---|---|---|
|
|
|
|||||
| No-early recurrence (n=121) | Early recurrence (n=93) | No-early recurrence (n=22) | Early recurrence (n=26) | |||
| Age (years), mean±SD | 50.8±12.7 | 50.7±11.8 | 0.967 | 53.8±9.1 | 58.5±12.7 | 0.082 |
|
| ||||||
| Sex, n (%) | ||||||
| Female | 15 (12.4) | 11 (11.8) | 0.900 | 2 (9.0) | 8 (30.8) | 0.137 |
| Male | 106 (87.6) | 82 (88.2) | 20 (90.9) | 18 (69.2) | ||
|
| ||||||
| Hepatitis B, n (%) | ||||||
| Negative | 10 (8.3) | 7 (7.5) | 0.843 | 6 (27.3) | 13 (50.0) | 0.109 |
| Positive | 111 (91.7) | 86 (92.5) | 16 (72.7) | 13 (50.0) | ||
|
| ||||||
| Hepatitis C, n (%) | ||||||
| Negative | 121 (100.0) | 92 (98.9) | 0.435 | 22 (100.0) | 23 (88.5) | 0.295 |
| Positive | 0 (0.0) | 1 (1.1) | 0 (0.0) | 3 (11.5) | ||
|
| ||||||
| Child-Pugh, n (%) | ||||||
| A | 117 (96.7) | 84 (90.3) | 0.053 | 22 (100.0) | 23 (88.5) | 0.295 |
| B | 4 (3.3) | 9 (9.7) | 0 (0.0) | 3 (11.5) | ||
|
| ||||||
| ALT*, n (%) | ||||||
| ≤40 U/L | 88 (72.7) | 66 (71.0) | 0.776 | - | - | - |
| >40 U/L | 33 (27.3) | 27 (29.0) | ||||
|
| ||||||
| AST*, n (%) | ||||||
| ≤40 U/L | 115 (95.0) | 91 (97.8) | 0.478 | - | - | - |
| >40 U/L | 6 (5.0) | 2 (2.2) | ||||
|
| ||||||
| AFP, n (%) | ||||||
| ≤400 ng/mL | 94 (77.7) | 56 (60.2) | 0.006 | 19 (86.4) | 22 (84.6) | 1.000 |
| >400 ng/mL | 27 (22.3) | 37 (39.8) | 3 (13.6) | 4 (15.4) | ||
|
| ||||||
| Radiologic evidence of cirrhosis*, n (%) | ||||||
| Absent | 53 (43.8) | 29 (31.2) | 0.060 | - | - | - |
| Present | 68 (56.2) | 64 (68.8) | ||||
|
| ||||||
| BCLC stage, n (%) | ||||||
| 0 + A | 111 (90.2) | 75 (80.0) | 0.017 | 20 (91.0) | 18 (69.2) | 0.137 |
| B | 10 (9.8) | 18 (20.0) | 2 (9.0) | 8 (30.8) | ||
|
| ||||||
| Tumor number, n (%) | ||||||
| ≤1 | 111 (91.7) | 73 (78.5) | 0.006 | 20 (91.0) | 18 (69.2) | 0.137 |
| >1 | 10 (8.3) | 20 (21.5) | 2 (9.0) | 8 (30.8) | ||
|
| ||||||
| Tumor size, n (%) | ||||||
| ≤5 cm | 81 (66.9) | 33 (35.5) | <0.001 | 13 (59.1) | 10 (38.5) | 0.154 |
| >5 cm | 40 (33.1) | 60 (64.5) | 9 (40.9) | 16 (61.5) | ||
|
| ||||||
| Radiomic signature score, median (interquartile range) | −0.94 (−1.60, −0.31) | 0.41 (−0.38, 1.19) | <0.001 | −0.89 (−1.27, −0.45) | 0.36 (−0.91, 1.45) | 0.008 |
SD, standard deviation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, serum alpha-fetoprotein; BCLC, Barcelona clinical liver cancer staging.
*
No corresponding variables recorded in TCIA&TCGA cohort.